Abstract
Process approaches and intensification technological processes are integrated parts of available devices, which have a positive effect on the parameters of the obtained products. Nanoemulsions as delivery carriers are becoming more popular and there is a real need to increase the possibilities of formulation designing and engineering. Therefore, preparations of oil-in-water nanoemulsion with encapsulated cannabidiol (CBD) as oil phase were carried out in two ways: sonication method and two-stage high-pressure homogenization. The provided analysis showed spherical morphology and much larger sizes and polydispersity of nanoemulsions obtained by the sonication approach. The size of nanodroplets was from 216 nm up to 1418 nm for sonication, whereas for homogenization 128–880 nm. Additionally, it was observed that a proportionally higher percentage of surfactin resulted in a higher value of the Zeta potential. The formulations were found to be stable for at least 30 days. The in vitro experiments performed on human skin cell lines (HaCaT keratinocytes and normal dermal NHDF fibroblasts), and in vivo topical tests on probants established the biocompatibility of nanoemulsions with CBD. The last stage exhibits reduced discoloration and a higher degree of hydration by the selected systems with CBD and, thus indicating this nanoformulation as useful in cosmetics applications.
Highlights
Cannabis (Cannabis sativa, L.) contains over 120 phytocannabinoids [1], but one of its main components is cannabidiol (CBD) (Figure 1)
The in vitro experiments performed on human skin cell lines (HaCaT keratinocytes and normal dermal NHDF fibroblasts), and in vivo topical tests on probants established the biocompatibility of nanoemulsions with CBD
Visual observations and Dynamic light scattering (DLS) analysis enable choosing forms creating the o/w nanoemulsions, where the stabilization process of the non-ionic polyethylene glycol sorbitan monooleate was assisted by an addiction of ionic surfactin
Summary
Cannabis (Cannabis sativa, L.) contains over 120 phytocannabinoids [1], but one of its main components is cannabidiol (CBD) (Figure 1). Epidiolex® , a CBD oil preparation, was approved by the US FDA for the treatment of Published: 7 July 2021 seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in June 2018. Since that time there has been a multitude of initial research studies indicating that CBD. The most studied with regard to jurisdictional claims in cannabinoids, tetrahydrocannabinol (∆9-THC) and CBD have shown promising results in published maps and institutional affilthe management of chronic pain. They have shown the capacity for limiting nausea iations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
